GSK Plc

NYSE: GSK
$41.24
+$0.65 (+1.6%)
Closing price April 23, 2024
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, arexvy, influenza, and pandemic vaccines. It also provides medicine products for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. The company sells its products under the Anoro Ellipta, Nucala, Trelegy Ellipta, Ventolin, Xevudy, Keppra, Augmentin, Zejula, Blenrep, Jemperli, Ojjaara/Omjjara, Benlysta, Benlysta, Jesduvroq, Duvroq, Apretude, Cabenuva/Vocabria + Rekambys, Rukobia, Dovato, Juluca, Triumeq, Tivicay, Arexvy, Bexsero, Menveo, Synflorix, and Shingrix brand names. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Berkshire Hathaway has released its public equity holdings as of December 31, 2016, and the number of changes in the equity portfolio were nothing short of massive.
With the markets warming up to the reality of a Donald Trump presidency and administration, some people have become nervous about dividend-paying stocks as they see higher interest rates and...
While these out-of-favor stocks may still remain volatile, buying these top companies at deep discounts may end up being one of the best trades for the rest of 2016 and 2017.
Some of the top European companies are offering outstanding dividends to investors, many of which are higher than their U.S. counterparts.
Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.
Rates are still near the lowest levels in history, but by the way dividend stocks are being sold, you would think the late 1970s and early 1980s were right around the corner.
With the 10-year Treasury yielding much less than 2% and the prospects for big capital gains going forward far lower than over the past 10 years, switching to top dividend stocks now looks like a...
The top analyst upgrades, downgrades and initiations seen on Friday morning include Activision Blizzard, Electronic Arts, Transocean, Twitter, Wal-Mart and Yum Brands.
It’s getting harder and harder for investors seeking income. Most investors are looking for yields that are at least 4% and have some degree of safety as well.
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
At 24/7 Wall St. we are constantly on the lookout for stocks that pay good dividends, are not horribly overbought and are rated reasonably high by some of the top firms we cover.
These three safe and relatively defensive stocks that pay solid dividends could be outstanding choices for income accounts looking to take utility gains and roll into something with better upside...
Though these clearly are stocks for more aggressive accounts, the total return potential is outstanding, and all of them do very well in their respective sectors.
Viagra, the wildly successful erectile dysfunction pill, faces challenges from a generic version that will launch next year.
The stock market has recovered a majority of its post-Brexit losses, with the Dow’s 900+ point drop from last Thursday to being less than 100 points down. Investors have different reasons each...